Altimmune (NASDAQ:ALT) CFO Gregory Weaver Buys 10,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory Weaver bought 10,000 shares of the company’s stock in a transaction on Friday, November 13th. The shares were acquired at an average cost of $1.62 per share, for a total transaction of $16,200.00. Following the completion of the acquisition, the chief financial officer directly owned 73,005 shares of the company’s stock, valued at $118,268.10. This trade represents a 15.87% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Altimmune Price Performance

ALT stock traded up $0.04 during trading on Friday, hitting $1.65. The company had a trading volume of 3,528,857 shares, compared to its average volume of 3,885,901. The business has a 50 day moving average of $2.58 and a 200 day moving average of $3.15. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $319.99 million, a price-to-earnings ratio of -2.28 and a beta of 0.16. Altimmune, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $6.44.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). As a group, research analysts predict that Altimmune, Inc. will post -0.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALT has been the topic of several analyst reports. Wall Street Zen lowered shares of Altimmune from a “sell” rating to a “strong sell” rating in a report on Saturday. Evercore reissued an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. B. Riley Financial reaffirmed a “buy” rating on shares of Altimmune in a research note on Friday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Friday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC raised its stake in shares of Altimmune by 14.7% in the third quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock worth $4,919,000 after purchasing an additional 220,000 shares during the last quarter. R Squared Ltd boosted its stake in Altimmune by 99.6% in the 3rd quarter. R Squared Ltd now owns 26,475 shares of the company’s stock worth $76,000 after purchasing an additional 13,211 shares during the period. StoneX Group Inc. bought a new position in shares of Altimmune in the third quarter worth $46,000. Parallel Advisors LLC lifted its position in Altimmune by 21,755.0% during the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock valued at $25,000 after purchasing an additional 8,702 shares during the last quarter. Finally, Alps Advisors Inc. lifted its stake in Altimmune by 29.6% during the third quarter. Alps Advisors Inc. now owns 255,875 shares of the company’s stock worth $732,000 after purchasing an additional 58,501 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Recent Altimmune Headlines

Investors following ALT have been watching these headlines:

• Positive Sentiment: Newly published 48-week Phase 2b IMPACT results showed pemvidutide improved non-invasive measures of liver fat, inflammation, and fibrosis, alongside weight loss and generally favorable tolerability. The findings support the ongoing Phase 3 PERFORMA MASH trial, though pemvidutide remains investigational. Trial results article
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
• Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.